GLP-1RA Effects on Lean Mass and Bone Health in Midlife Women

GLP-1RA Effects on Lean Mass and Bone Health in Midlife Women

This study is designed with the interest to learn on the effects of estrogen levels and how it affects body compositions and muscle function in midlife women who are taking a GLP-1RA for weight loss.

Inclusion Criteria:

• Females
• Age 35-60 year
• BMI≥30 or BMI≥27 and at least one cardiometabolic risk factor (dyslipidemia, hypertension, obstructive sleep apnea, metabolic syndrome, fatty liver, PCOS)
• Newly prescribed a GLP-1RA medication
• English speaking
• Body weight stable for the past 6 months

Exclusion Criteria:

• Pregnant women
• Under age 35 or over age 60
• Born male
• Cannot consent for themselves
• Cannot read and speak in English
• Type 2 diabetes
• Recently discontinued a GLP-1RA medication (less than 6-months since discontinuing)
• Contraindications for taking a GLP-1 RA medication (personal or family history of medullary thyroid carcinoma, personal or family history of multiple endocrine neoplasia type 2, personal history of pancreatitis, pregnancy, hypersensitivity to the drug or any component of the drug, active suicidal ideation)
• Currently taking aromatase inhibitors or selective estrogen receptor modulators (SERMs)